Company profile

Occlufit AG

Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects. Occlufit treats patients with a percutaneous approach for left atrial appendage closure (LAAC), to prevent stroke, thrombosis and bleeding. The global LAAC market will reach $958M by 2025, with a growth of 19.8%/y. Occlufit is the only device based on a balloon that can conform to any different heart geometry. Existing devices are based on a non-adaptable shape and their rigid metallic mesh requires endothelization for sealing, delaying the protective effect. The lack of adaptation to variable LAA shapes can lead to incomplete efficacy or device migration. Occlufit pipeline includes occluder devices for paravalvular leaks, congenital defects, and endovascular leak.

More news about Occlufit AG

11.06.2019 14:01

Occlufit joins the UZH Life Sciences Fund portfolio

Please login or
register to use the
awards follow feature
Occlufit AG

Founded
2018

Kanton
ZH

Homepage

rss